Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes
In ACHIEVE-1, orforglipron also led to an average weight loss of 16.0 lbs (7.9%) at the highest dose by week 40 in a key secondary endpoint
The safety profile of orforglipron was consistent with the established GLP-1 class
INDIANAPOLIS, June 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orforglipron is the first oral small molecule (non-peptide) glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial. At 40 weeks, all three doses (3 mg, 12 mg, 36 mg) of orforglipron achieved the primary endpoint of superior A1C reduction. In addition, the 12 mg and 36 mg doses showed clinically meaningful and statistically significant reductions in body weight vs. placebo. In the study, orforglipron had a safety profile similar to the established GLP-1 class, and the most frequently reported adverse events were gastrointestinal-related. The results were presented at the American Diabetes Association (ADA) 85th Scientific Sessions 2025 and simultaneously published in The New England Journal of Medicine.
In the study, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by 1.3% to 1.6% from a baseline of 8.0%, for the efficacy estimand.1 In key secondary endpoints, up to 76.2% of participants taking orforglipron achieved the ADA treatment target A1C of <7%, 66.0% achieved an A1C of ≤6.5%, and 25.8% achieved <5.7%, defined as a normal A1C value.2,3 Improvements in A1C were observed as early as four weeks and were accompanied by similar reductions in fasting serum glucose. In another key secondary endpoint, participants taking the highest dose of orforglipron lost an average of 16.0 lbs (7.9%). While participants in ACHIEVE-1 did not appear to reach a weight plateau, longer-duration trials, such as the ATTAIN trials, will provide a comprehensive evaluation of the safety and efficacy of orforglipron for the treatment of obesity.
"The ACHIEVE-1 trial demonstrated that orforglipron, a novel oral small-molecule GLP-1, achieved clinically meaningful reductions in A1C and body weight over 40 weeks in adults with type 2 diabetes," said Dr. Julio Rosenstock, senior scientific advisor for Velocity Clinical Research at Medical City Dallas, clinical professor of medicine, University of Texas Southwestern Medical Center, and lead trial investigator. "The early onset of glycemic improvement, observed as soon as four weeks, reinforces the therapeutic potential of orforglipron as an effective, oral GLP-1 therapy for early type 2 diabetes treatment. These findings support further investigation in broader populations and longer-duration studies."
Full ResultsOrforglipron
3 mg
Orforglipron
12 mg
Orforglipron
36 mg
Placebo
Primary Endpoint
A1C reduction from
baseline of 8.0 %i
Efficacy estimand
1.3 %
1.6 %
1.5 %
0.1 %
Treatment-regimen
estimand4
1.2 %
1.5 %
1.5 %
0.4 %
Key Secondary Endpointsii
Percent weight reduction
from baseline of 90.2 kg
(198.9 lbs)i,iii
Efficacy estimand
4.7 %
6.1 %
7.9 %
1.6 %
Treatment-regimen
estimand
4.5 %
5.8 %
7.6 %
1.7 %
Weight reduction from
baseline of 90.2 kg
(198.9 lbs)i,iii
Efficacy estimand
4.4 kg (9.7 lbs)
5.5 kg (12.2 lbs)
7.3 kg (16.0 lbs)
1.3 kg
(2.9 lbs)
Treatment-regimen estimand
4.2 kg
(9.3 lbs)
5.2 kg
(11.5 lbs)
7.2 kg
(15.8 lbs)
1.5 kg
(3.4 lbs)
Percent of participants
achieving A1C <7 %i
Efficacy estimand
72.9 %
76.2 %
74.9 %
28.0 %
Treatment-regimen
estimand
68.1 %
72.9 %
72.7 %
33.0 %
Percent of participants
achieving A1C ≤6.5 %i,ii
Efficacy estimand
61.5 %
62.3 %
66.0 %
13.5 %
Treatment-regimen estimand
56.9 %
58.1 %
61.9 %
14.9 %
Percent of participants achieving A1C <5.7 %iii
Efficacy estimand
17.7 %
25.8 %
23.9 %
3.8 %
Treatment-regimen
estimand
16.8 %
23.9 %
21.5 %
3.8 %
Fasting serum glucose reduction from baseline
of 147.5 mg/dLi
Efficacy estimand
30.6 mg/dL
37.4 mg/dL
37.8 mg/dL
1.1 mg/dL
Treatment-regimen
estimand
30.7 mg/dL
36.5 mg/dL
34.7 mg/dL
10.8 mg/dL
iSuperiority test was adjusted for multiplicity.iiData from the full list of key secondary endpoints are available in the publication.iiiPercent of participants achieving A1C <5.7% across all orforglipron doses and body weight for orforglipron 3 mg were not controlled for Type 1 error.
"This convenient once-daily pill with no restrictions on food and water intake could be an option for millions of people with type 2 diabetes who prefer oral medications over injectables," said Jeff Emmick, M.D., Ph.D., senior vice president of product development at Lilly. "The positive ACHIEVE-1 results position orforglipron as a potential treatment option with meaningful A1C and weight reduction, and a safety profile similar to injectable GLP-1 therapies. We look forward to the four remaining global readouts from the ACHIEVE program, as well as results of the ATTAIN program in obesity, and working with regulators to bring this once-daily oral GLP-1 to people around the world."
The overall safety profile of orforglipron in ACHIEVE-1 was consistent with the established GLP-1 class. The most common adverse events for participants treated with orforglipron (3 mg, 12 mg and 36 mg, respectively) were diarrhea (19%, 21% and 26%) vs. 9% with placebo, nausea (13%, 18% and 16%) vs. 2% with placebo, dyspepsia (11%, 20% and 15%) vs. 7% with placebo, constipation (8%, 17% and 14%) vs. 4% with placebo, and vomiting (5%, 7% and 14%) vs. 1% with placebo. These gastrointestinal-related adverse events were generally mild-to-moderate in severity and occurred primarily during dose escalation. Overall treatment discontinuation rates due to adverse events were 6% (3 mg), 4% (12 mg) and 8% (36 mg) for orforglipron vs. 1% with placebo. No hepatic safety signal was observed.
Later this year, Lilly expects to share topline results from ACHIEVE-2, evaluating orforglipron compared with dapagliflozin, and ACHIEVE-3, evaluating orforglipron compared to oral semaglutide, both in adults with type 2 diabetes inadequately controlled with metformin. ATTAIN-1 and ATTAIN-2, evaluating orforglipron for weight management, will also be shared in the third quarter of this year. Lilly remains on track to submit orforglipron for weight management to global regulatory agencies by the end of this year and for the treatment of type 2 diabetes in 2026.
About orforglipron Orforglipron (or-for-GLIP-ron) is an investigational, once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.5 Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. Chugai and Lilly published the preclinical pharmacology data of this molecule together.6 Lilly is running Phase 3 studies on orforglipron for the treatment of type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related medical problem. It is also being studied as a potential treatment for obstructive sleep apnea and hypertension in adults with obesity.
About ACHIEVE-1 and the ACHIEVE clinical trial program ACHIEVE-1 (NCT05971940) is a Phase 3, 40-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron 3 mg, 12 mg and 36 mg as monotherapy to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The trial randomized 559 participants across the U.S., China, India, Japan and Mexico in 1:1:1:1 ratio to receive either 3 mg, 12 mg or 36 mg orforglipron or placebo. The primary objective of the study was to demonstrate that orforglipron (3 mg, 12 mg, 36 mg) is superior in A1C reduction from baseline after 40 weeks, compared to placebo, in people with type 2 diabetes who have not taken any anti-diabetic medications for at least 90 days prior to visit 1, and are naïve to insulin therapy. Study participants had a HbA1c between ≥7.0% and ≤9.5% and a BMI of ≥23 kg/m2. All participants in the orforglipron treatment arms started the study at a dose of orforglipron 1 mg once-daily and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 3 mg (via a 1 mg step), 12 mg (via steps at 1 mg, 3 mg and 6 mg) or 36 mg (via steps at 1 mg, 3 mg, 6 mg, 12 mg and 24 mg). Flexible dosing was not permitted.
The ACHIEVE Phase 3 global clinical development program for orforglipron has enrolled more than 6,000 people with type 2 diabetes across five global registration trials. The program began in 2023 with results anticipated later this year and into 2026.
About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY
The efficacy estimand represents the treatment effect had on all participants who adhered to the study drug (with possible dose interruptions) for 40 weeks without initiating additional antihyperglycemic medications (>14 days of use).
American Diabetes Association. Standards of Care in Diabetes—2020 Abridged for Primary Care Providers. Clinical Diabetes 2020; 38(1):10–38. https://doi.org/10.2337/cd20-as01
Percent of participants achieving A1C <5.7% across all doses was not controlled for Type 1 error.
The treatment-regimen estimand represents the estimated average treatment effect regardless of treatment discontinuation or initiation of additional antihyperglycemic medications.
Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832. https://doi.org/10.1007/s13300-024-01554-1. Epub 2024 Feb 24. PMID: 38402332; PMCID: PMC10951152.
T. Kawai, B. Sun, H. Yoshino, D. Feng, Y. Suzuki, M. Fukazawa, S. Nagao, D.B. Wainscott, A.D. Showalter, B.A. Droz, T.S. Kobilka, M.P. Coghlan, F.S. Willard, Y. Kawabe, B.K. Kobilka, & K.W. Sloop, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967, https://doi.org/10.1073/pnas.2014879117 (2020).
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about orforglipron as a potential treatment for adults with type 2 diabetes, and the timeline for future readouts, presentations, and other milestones relating to orforglipron and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that orforglipron will prove to be a safe and effective treatment for type 2 diabetes, that orforglipron will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Refer to:
Brooke Frost; brooke.frost@lilly.com; 317-432-9145 (Media)Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-showed-compelling-efficacy-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-complete-phase-3-results-published-in-the-new-england-journal-of-medicine-302487392.html
SOURCE Eli Lilly and Company
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
The average healthcare stock has a yield of just 1.7%. Medtronic's dividend yield is 3.3%. Alexandria Real Estate Equities' yield is 7.4%. 10 stocks we like better than Medtronic › The healthcare sector isn't exactly known for offering huge yields, with Health Care Select Sector SPDR (NYSEMKT: XLV) offering a yield of just 1.7%. If dividend investors take some time to dig into the sector, however, they can do much better. For example, Medtronic (NYSE: MDT) has a 3.3% yield today, and Alexandria Real Estate Equities (NYSE: ARE) is offering a yield of 7.4%. Here's what you need to know about each of these high-yield healthcare stocks. Medtronic makes medical devices. It is one of the largest competitors in the space, making products across the cardiovascular, neuroscience, medical surgical, and diabetes categories. It has a leading position in each of the areas in which it operates, and it operates on a global scale. That said, the last few years haven't been the best ones for the company. Innovation, which is highly important in the healthcare space, can be lumpy. And given Medtronic's size, the business has become a little cumbersome. Growth has stalled out, and profitability has come under pressure. Investors have focused on the negatives pushing the shares lower and the dividend yield up toward the high end of Medtronic's historical yield range. If you are a dividend investor that thinks in decades and not days, however, this is likely to be an investment opportunity. The company's innovation pipeline is starting to turn into new-product introductions. As new products gain traction, financial performance is likely to improve. And management has been working to streamline the business with cost cuts and a move to refocus on its most profitable operations. To that end, the company is set to spin off its lower-margin diabetes division in 2026. The move is expected to be immediately accretive to earnings, and the dividend policy isn't expected to change. All in, Medtronic is doing what it needs to do to get back on the growth path. And that should support continued dividend increases; the medical device maker only has two years to go before it hits Dividend King status (50+ years of annual dividend increases). June could be an opportune time to buy the stock hand over fist. Alexandria is a real estate investment trust (REIT), which seems pretty far away from healthcare. Its primary focus is on office properties, which also seems a bit removed from healthcare. The key here is that the REIT owns biomedical research facilities, which combine research space and office space in one property. Both are important to each other since the research takes place in specialized space, while the analysis of that research takes place in a normal office environment. Alexandria is one of the largest pure play medical research REITs you can buy. Alexandria counts some of the largest and most important medical research groups as tenants, from both the private side of the equation and the government side. However, like any landlord, the REIT's revenues will be impacted by the occupancy levels of its properties. And those rise and fall over time. Right now, occupancy is relatively weak, dropping to 91.7% at the end of the first quarter of 2025 from 94.6% at the end of 2024. Swings like this happen from time to time, but Wall Street is treating Alexandria as if its dividend is at a material risk of being cut. Only the funds from operations (FFO) payout ratio in the first quarter was a fairly strong 57%. There's room for adversity before a dividend cut would be in order. To be fair, office properties, and particularly highly specialized office properties, tend to have higher operating costs than other real estate assets. But it seems highly likely that Alexandria will manage its way through this weak patch and continue to extend its 15-year streak of annual dividend increases. For income lovers, this healthcare REIT is worth a deep dive in June. The average healthcare stock has an uninspiring dividend yield. But the average is made up of many different companies, some of which actually have very attractive dividend yields. That list includes industry-leading companies like Medtronic and Alexandria Real Estate. You might just want to pick up shares in one, or both, of these high yielders before June is over after you get to know them a little better. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Alexandria Real Estate Equities. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. 2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
an hour ago
- Washington Post
Transgender troops want to keep serving. Trump is forcing them out.
U.S. Space Force Master Sgt. Sabrina Bruce didn't know her life was about to change forever when she got into her car last month to head to the Pentagon and reenlist for another six years. Bruce, 34, was excited to continue a career that had set her on a life-altering path. She'd enlisted in the Air Force in 2013 to escape her gender dysphoria, she said, referring to the medical term for the distress felt when one's sex assigned at birth does not align with their gender. Instead, she found a culture that empowered her to come out as a transgender woman.
Yahoo
an hour ago
- Yahoo
I can think of so many things I love. I'll bet you can, too, and it's empowering
Most friendships include the occasional commiseration conversation. When we're young, those discussions center on homework or dating or parental interference. Eventually, we graduate to work disputes, financial woes and relationship friction. Alas, I've reached the age at which those conversations are constant rather than occasional, and the sources of angst generally are weight gain, politics and maladies. I pride myself on being a positive person, but sometimes waking up with aching knees and a bum shoulder can get depressing. Add to that a volatile stock market, sketchy medical bills and a car issue that may, or may not, be covered by warranty, and it's easy to wallow. Then a friend shared this quote: 'Focus on the things you are for, not the things you are against. Many people spend large chunks of their day thinking about what they hate. They are always telling you about something they dislike: this food, that subject, this political party, that co-worker. You are more than your frustrations. Build your identity around what you love.' It's attributed to James Clear, author of 'Atomic Habits,' though the Google could neither confirm nor deny its origins. Regardless, the message is empowering. So here goes, a few things I love: — I've taken up swimming for the second summer. I've worked my way up to swimming three times a week, one mile at a time. I've learned not to plan anything within two hours of a swim session, because it takes me that long to stop sweating. The thing I love most about swimming? I barely feel those achy joints anymore. — The babies have grown up and gone to college. The toddlers have toddlers of their own. That's how long my family has been gathering for our annual summer reunions. You'd think we'd be tired of them by now, but we're not. This year's trip is three weeks out, and the phone calls and group texts are in full swing as we plan meals, field trips and cabin assignments. I've also started stocking up on Publix BOGOs. (Yay for free Pop-Tarts!) — I recently started driving a new-to-me car that came equipped with Apple CarPlay. How have I driven four and a half decades without being able to shuffle my Pandora stations? Any drive is better when it features Billy Joel, Bonnie Raitt, Tyler Childers, the Partridge Family, Marcia Ball and Willie Nelson. It's also kind of awesome having an on-screen map that tells me when I'm 12 minutes from home. — After 21 years of marriage, my husband knows I'm dead calm when I've sliced off the tip of my finger while cutting potatoes. Blood-curdling screams are saved for flying roaches. — I have solved one of the world's greatest mysteries: Where errant socks go. Turns out we're not paranoid. The washing machine really does eat them. At least mine does. Socks like to get caught in the rubber gasket that seals my front-load washer. Sorry, pups. Didn't mean to wrongly accuse you. — And while we're talking about pups, my life is good. There are people who are literally allergic to dogs. — I love having friends who run the gamut when it comes to age, gender and political preferences. They make me smarter, and they make me laugh. They help me understand different perspectives, and they validate my beliefs. A life of homogeneity would be so dull. These are just a few of the things around which I want to build my identity. Now it's your turn. Will you focus on the things you love? Or will you let the things you hate define you? Suzy Fleming Leonard is a retired journalist who spent 25 years as a writer, editor and columnist at FLORIDA TODAY. Reach her at suzy@ This article originally appeared on Florida Today: When you fill your life with love, there's no room for hate | Leonard
